bluebird bio (BLUE) PT Lowered to $14 at RBC Capital
Tweet
Share
E-mailGet Alerts BLUE Hot Sheet
Price: $1.02 +7.37%
Rating Summary:
13 Buy, 16 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
13 Buy, 16 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
RBC Capital analyst Luca Issi lowered the price target on bluebird bio (NASDAQ: BLUE) to $14.00 (from $26.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
- Johnson Matthey PLC (JMAT:LN) (JMPLY) PT Raised to GBP21.70 at Barclays
- L'Oreal SA (OR:FP) (LRLCY) PT Raised to EUR480 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
